122 related articles for article (PubMed ID: 38479168)
1. Imidazo[1,2-b]pyridazines as inhibitors of DYRK kinases.
Henderson SH; Sorrell FJ; Bennett JM; Fedorov O; Hanley MT; Godoi PH; Ruela de Sousa R; Robinson S; Navratilova IH; Elkins JM; Ward SE
Eur J Med Chem; 2024 Apr; 269():116292. PubMed ID: 38479168
[TBL] [Abstract][Full Text] [Related]
2. Exploration of the imidazo[1,2-b]pyridazine scaffold as a protein kinase inhibitor.
Bendjeddou LZ; Loaëc N; Villiers B; Prina E; Späth GF; Galons H; Meijer L; Oumata N
Eur J Med Chem; 2017 Jan; 125():696-709. PubMed ID: 27721154
[TBL] [Abstract][Full Text] [Related]
3. Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship.
Shimizu H; Tanaka S; Toki T; Yasumatsu I; Akimoto T; Morishita K; Yamasaki T; Yasukochi T; Iimura S
Bioorg Med Chem Lett; 2010 Sep; 20(17):5113-8. PubMed ID: 20675134
[TBL] [Abstract][Full Text] [Related]
4. Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
Henderson SH; Sorrell F; Bennett J; Fedorov O; Hanley MT; Godoi PH; Ruela de Sousa R; Robinson S; Ashall-Kelly A; Hopkins Navratilova I; Walter DS; Elkins JM; Ward SE
J Med Chem; 2021 Aug; 64(15):11709-11728. PubMed ID: 34342227
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
[TBL] [Abstract][Full Text] [Related]
6. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S
Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937
[TBL] [Abstract][Full Text] [Related]
7. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: exploration of effective compounds in arthritis models.
Shimizu H; Yamasaki T; Yoneda Y; Muro F; Hamada T; Yasukochi T; Tanaka S; Toki T; Yokoyama M; Morishita K; Iimura S
Bioorg Med Chem Lett; 2011 Aug; 21(15):4550-5. PubMed ID: 21705219
[TBL] [Abstract][Full Text] [Related]
8. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
[TBL] [Abstract][Full Text] [Related]
9. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
10. Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1.
Moine E; Dimier-Poisson I; Enguehard-Gueiffier C; Logé C; Pénichon M; Moiré N; Delehouzé C; Foll-Josselin B; Ruchaud S; Bach S; Gueiffier A; Debierre-Grockiego F; Denevault-Sabourin C
Eur J Med Chem; 2015 Nov; 105():80-105. PubMed ID: 26479029
[TBL] [Abstract][Full Text] [Related]
11. Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors.
Byth KF; Cooper N; Culshaw JD; Heaton DW; Oakes SE; Minshull CA; Norman RA; Pauptit RA; Tucker JA; Breed J; Pannifer A; Rowsell S; Stanway JJ; Valentine AL; Thomas AP
Bioorg Med Chem Lett; 2004 May; 14(9):2249-52. PubMed ID: 15081018
[TBL] [Abstract][Full Text] [Related]
12. Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 2: improvement of potency in vitro and in vivo.
Shimizu H; Yasumatsu I; Hamada T; Yoneda Y; Yamasaki T; Tanaka S; Toki T; Yokoyama M; Morishita K; Iimura S
Bioorg Med Chem Lett; 2011 Feb; 21(3):904-8. PubMed ID: 21232950
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of imidazo[1,2-b]pyridazine derivatives having a benzamide unit as novel VEGFR2 kinase inhibitors.
Miyamoto N; Oguro Y; Takagi T; Iwata H; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2012 Dec; 20(24):7051-8. PubMed ID: 23123015
[TBL] [Abstract][Full Text] [Related]
14. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
Pogacic V; Bullock AN; Fedorov O; Filippakopoulos P; Gasser C; Biondi A; Meyer-Monard S; Knapp S; Schwaller J
Cancer Res; 2007 Jul; 67(14):6916-24. PubMed ID: 17638903
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.
Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H
Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679
[TBL] [Abstract][Full Text] [Related]
16. Diabetic Kinome Inhibitors-A New Opportunity for β-Cells Restoration.
Pucelik B; Barzowska A; Dąbrowski JM; Czarna A
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445786
[TBL] [Abstract][Full Text] [Related]
17. Generation of highly potent DYRK1A-dependent inducers of human β-Cell replication via Multi-Dimensional compound optimization.
Allegretti PA; Horton TM; Abdolazimi Y; Moeller HP; Yeh B; Caffet M; Michel G; Smith M; Annes JP
Bioorg Med Chem; 2020 Jan; 28(1):115193. PubMed ID: 31757680
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy and Selectivity of Pharmacological Inhibitors of DYRK and CLK Protein Kinases.
Lindberg MF; Deau E; Arfwedson J; George N; George P; Alfonso P; Corrionero A; Meijer L
J Med Chem; 2023 Mar; 66(6):4106-4130. PubMed ID: 36876904
[TBL] [Abstract][Full Text] [Related]
19. Structure Activity Relationship Studies around
Brahmaiah D; Bhavani AKD; Aparna P; Kumar NS; Solhi H; Le Guevel R; Baratte B; Robert T; Ruchaud S; Bach S; Jadav SS; Reddy CR; Mosset P; Gouault N; Levoin N; Grée R
Molecules; 2022 Sep; 27(19):. PubMed ID: 36234686
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
